Rapid declines in total lymphocyte count and hemoglobin in HIV infection begin at CD4 lymphocyte counts that justify antiretroviral therapy
Gange, Stephen Ja; Lau, Bryana; Phair, Johnc; Riddler, Sharon Ad; Detels, Rogere; Margolick, Joseph Bb
Departments of aEpidemiology and bMolecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA; cNorthwestern University Medical School, Chicago, IL, USA; dUniversity of Pittsburgh, Pittsburgh, PA, USA; and eUCLA School of Pf Public Health, Los Angelesles, CA, USA.
Received and accepted: 7 August 2002.
We investigated whether the onset of rapid declines in total lymphocyte counts and hemoglobin levels might be useful for staging HIV disease and initiating antiretroviral therapy. Using data from the Multicenter AIDS Cohort Study, we found that accelerated declines in both markers generally precede AIDS by 1.2 years and occur when the CD4 lymphocyte counts fall below 350 cells/mm3. These markers may thus be suitable for monitoring disease and timing therapy initiation in resource-limited settings.
There is an emerging consensus that the HIV pandemic in the developing world requires treatment with antiretroviral drugs . However, because of the complexity, expense, and diversity of potentially effective treatments, there is not yet consensus on what treatments should be given and at what stage of HIV infection they should be initiated. In the developed world, guidelines for starting treatment are based on the CD4 lymphocyte counts and plasma HIV-RNA concentration , but these markers are considered impractical for widespread use in the developing world because of their expense and other factors.
One marker that has been proposed for resource-limited settings is the total lymphocyte count (TLC). Current WHO guidelines recommend the use of TLC counts below 1200 cells/mm3 , although data supporting the use of this marker have been mixed [4–7]. One challenge to using TLC for predicting the disease stage is that it does not show a linear decline throughout HIV infection, but rather a period of stability followed by a more rapid decline preceding clinically defined AIDS . Furthermore, TLC can also be affected by a number of factors independent of disease progression.
Therefore, using our understanding of the longitudinal patterns of TLC, we hypothesized that the rapid change in these markers could distinguish those with and without incipient AIDS. For this analysis, we used the extensive data from the Multicenter AIDS Cohort Study collected before the advent of potent antiretroviral therapy, which has supported the use of CD4 cell counts and HIV-RNA levels as markers of disease progression . In addition to TLC, we also evaluate hemoglobin, which has also been shown to correlate with the progression to AIDS under certain circumstances [10,11], declines around the time of AIDS , and is also relatively inexpensive and straightforward to measure.
Of the 2770 HIV-infected men enrolled in the Multicenter AIDS Cohort Study, we restricted our analysis to 1455 men who provided marker data for at least four AIDS-free visits to October 1994 (before the use of protease inhibitors and the widespread use of stavudine and lamivudine), who either remained AIDS-free as of July 1997 or developed AIDS before October 1994, and contributed at least two visits within the 1.5 years preceding AIDS. Data obtained at the baseline visit of the seroprevalent men, and in the first year after seroconversion in the seroincident men, were excluded to avoid changes occurring around seroconversion. The median (interquartile range, IQR) number of marker measurements per individual was 12 (8–17).
We modified methods previously applied to the retrospective identification of inflections in total T lymphocyte counts [13,14] and viral load measurements  to determine the occurrence and timing of the onset of rapid declines in TLC and hemoglobin. For each marker, we estimated the magnitude of decline that best distinguished men who did or did not develop AIDS over follow-up. To enhance the stability of our estimates, declines were calculated as the difference between the mean of the two most recent marker values from the mean of all previous marker values. The rates of decline that best (i.e. with maximal sensitivity and specificity) distinguished men with and without the onset of AIDS were 33% per year for TLC and 11.6% per year for hemoglobin. These optimal values provided sensitivity and specificity values of approximately 70% for TLC and 74% for hemoglobin. Similar results were obtained when restricting the analysis to seroconverters (data not shown).
We then identified the time that a decline of these magnitudes began over the course of follow-up (termed ‘inflection point'). The median (IQR) time from the inflection point to AIDS was 1.27 years (0.48, 2.64) for TLC and 1.21 years (0.49, 2.49) for hemoglobin. Fig. 1 shows longitudinal markers from two representative individuals who developed AIDS, displaying the first time that rapid changes (inflections) were identified.
To examine the distribution of these times relative to the first times that the CD4 lymphocyte counts fell below 350 cells/mm3 (i.e. the time at which the initiation of antiretroviral therapy is recommended ), we restricted our sample to the 432 men who had a baseline CD4 lymphocyte count greater than 500 cells/mm3, which fell below 350 cells/mm3 at some later time. Our analysis demonstrated that in the vast majority of cases the onset of rapid declines in TLC and hemoglobin occurred within several months of the time when the CD4 lymphocyte counts fell below 350 cells/mm3. The hemoglobin decline preceded the CD4 lymphocyte decline to less than 350 cells/mm3 by a median (IQR) time of 0.35 years (−1.37, +0.64), and the TLC decline followed the time that the CD4 lymphocyte count fell to less than 350 cells/mm3 by 0.11 years (−0.88, +0.62). At the first time when the CD4 lymphocyte counts fell below 350 cells/mm3, the median (IQR) level of TLC was 2088 cells/mm3 (1728, 2499) and hemoglobin was 15.1 g/dl (14.5, 15.8).
These results suggest that the onset of a rapid decline in TLC or hemoglobin could be a clinically valid indicator of a CD4 lymphocyte count that would justify initiating antiretroviral therapy. It is quite likely that the changes in these markers, which are inexpensive and widely available, could have significant value for the prospective monitoring of disease progression and the timing of the initiation of antiretroviral therapy in settings where it is not feasible to follow CD4 lymphocyte counts. The variability in the timing of inflections might be further reduced by considering marker combinations in conjunction with clinical conditions. These observations should be tested in appropriate populations, taking into account factors such as nutrition and endemic diseases that may affect these markers, as well as the frequency of monitoring that would be needed to obtain appropriate precision in the timing of the initiation of therapy.
Data in this manuscript were collected by the Multicenter AIDS Cohort Study, with centers (principal investigators) at the Johns Hopkins University Bloomberg School of Public Health (Joseph B. Margolick, Alvaro Muñoz), the Howard Brown Health Center and Northwestern University Medical School (John Phair), the University of California, Los Angeles (Roger Detels, Beth Jamieson), and the University of Pittsburgh (Charles Rinaldo). The Multicenter AIDS Cohort Study is funded by the National Institute of Allergy and Infectious Diseases, with additional supplemental funding from the National Cancer Institute, UO1-AI-35042, 5-MO1-RR-00722 (GCRC), UO1-AI-35043, UO1-AI-37984, UO1-AI-35039, UO1-AI-35040, UO1-AI-37613, UO1-AI-35041. Website located at http://www.statepi.jhsph.edu/macs/macs.html.
1.Weidle PJ, Mastro TD, Grant AD, Nkengasong J, Macharia D. HIV/AIDS treatment and HIV vaccines for Africa. Lancet 2002, 359:2261–2267.
2.Centers for Disease Control and Prevention. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents: recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR 2002, 51 (No. RR-7):1–55.
3.World Health Organization. Scaling up antiretroviral therapy in resource-limited settings. Guidelines for a public health approach.
Available at http://www.who.int/HIV_AIDS
Accessed 1 July 2002.
4.Blatt SP, Lucey CR, Butzin CA, Hendrix CW, Lucey DR. Total lymphocyte count as a predictor of absolute CD4+ count and CD4+ percentage in HIV-infected patients. JAMA 1993, 269:622–626.
5.Beck EJ, Kupek EJ, Gompels MM, Pinching AJ. Correlation between total and CD4 lymphocyte counts in HIV infection: not making the good an enemy of the not so perfect. Int J STD AIDS 1996, 7:422–428.
6.Post FA, Wood R, Maartens G. CD4 and total lymphocyte counts as predictors of HIV disease progression. Q J Med 1996, 89:505–508.
7.van der Ryst E, Kotze M, Joubert G, Steyn M, Pieters H, van der Westhuizen M, et al. Correlation among total lymphocyte count, absolute CD4+ count, and CD4+ percentage in a group of HIV-1 infected South African patients. J AIDS 1998, 19:238–244.
8.Margolick JB, Munoz A, Donnenberg AD, Park LP, Galai N, Giorgi JV, et al. Failure of T-cell homeostasis preceding AIDS in HIV-1 infection. The Multicenter AIDS Cohort Study. Nat Med 1995, 1:674–680.
9.Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997, 126: 946–954.
10.Moore RD, Keruly JC, Chaisson RE. Anemia and survival in HIV infection. J AIDS 1998, 19:29–33.
11.Mocroft A, Kirk O, Barton SE, Dietrich M, Proenca R, Colebunders R, et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS 1999, 13:943–950.
12.Hoover DR, Saah A, Bacellar H, Murphy R, Visscher B, Metz S, et al. The progression of untreated HIV-1 infection prior to AIDS. Am J Public Health 1992, 82:1538–1541.
13.Gange SJ, Munoz A, Chmiel JS, Donnenberg AD, Kirstein LM, Detels R, Margolick JB. Identification of inflections in T-cell counts among HIV-1-infected individuals and relationship with progression to clinical AIDS. Proc Natl Acad Sci U S A 1998, 95:10848–10853.
14.Maas J, Gange SJ, Schuitemaker H, Coutinho R, van Leeuwen R, Margolick JB. Strong association between failure of T-cell homeostasis and the syncytium-inducing phenotype among HIV-1 infected men in the Amsterdam Cohort Study. AIDS 2000, 14:1155–1161.
15.Gange SJ, Mellors JW, Lau B, Detels R, Phair JP, Muñoz A, Margolick JB. Longitudinal patterns of HIV-1 RNA among individuals with late disease progression. AIDS Res Hum Retroviruses 2001, 17:1223–1229.
© 2003 Lippincott Williams & Wilkins, Inc.